Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Long-Term Deferred Tax (2024 - 2025)

Fate Therapeutics (FATE) has disclosed Long-Term Deferred Tax for 2 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Deferred Tax rose 100.35% year-over-year to $2.3 million, compared with a TTM value of $2.3 million through Dec 2025, up 100.35%, and an annual FY2025 reading of $2.3 million, up 100.35% over the prior year.
  • Long-Term Deferred Tax was $2.3 million for Q4 2025 at Fate Therapeutics, up from $1.1 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $2.3 million in Q4 2025 and bottomed at $1.1 million in Q4 2024.